Zolmitriptan

Routes
Oral (PO)
Half-Life (t½)
PO: 3h
Formula
C16H21N3O2
Molecular Weight
287.36 g/mol
PubChem CID
60857
Aliases
Zomig

Pharmacological Mechanism

Selective 5-HT1B/1D receptor agonist (triptan) for acute migraine — cranial vasoconstriction and trigeminal inhibition; also binds 5-HT1F. Active N-desmethyl metabolite.

Half-Life & Elimination Curve (PO: 3h)

100%50%25%12.5%0%0h0×t½3h1×t½6h2×t½9h3×t½12h4×t½15h5×t½0×t½ (0h): 100% remaining (~1.45 µg/L)1×t½ (3h): 50% remaining (~0.726 µg/L)2×t½ (6h): 25% remaining (~0.363 µg/L)3×t½ (9h): 12.5% remaining (~0.181 µg/L)4×t½ (12h): 6.3% remaining (~0.0907 µg/L)5×t½ (15h): 3.1% remaining (~0.0454 µg/L)
Plasma (PO)t½ Decay (3h)Effect Site (ke0)
  • 0×t½0h100% (1.45 µg/L)
  • 1×t½3h50% (0.726 µg/L)
  • 2×t½6h25% (0.363 µg/L)
  • 3×t½9h12.5% (0.181 µg/L)
  • 4×t½12h6.3% (0.0907 µg/L)
  • 5×t½15h3.1% (0.0454 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.47h
Est. Peak (Cmax)1.45 µg/L
Clearance (CL)113 L/h
97% Washout (5×t½)15h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Target Organ Systems

Notes

PK from FDA prescribing information (DailyMed setid 333caafc-2e63-49f8-a0c6-534e528d228d): mean absolute bioavailability ~40% (F 0.4), apparent Vd 7 L/kg (~490 L), elimination t½ ~3 h, Tmax ~1.5 h (tablet). ka_hr 1.5 derived from Tmax 1.5 h (ke from t½ 3 h).

Chemical Structure & Identifiers

References